Traditional Chinese medicine compound and its application in preparing products for preventing and treating gastric mucosal damage

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and discloses a Chinese medicine compound and its application in preparing a product for preventing and treating gastric mucosal damage, wherein the application is the application of the Chinese medicine compound in preparing a product for reducing and treating diseases by regulating inflammatory cytokines, the application of the Chinese medicine compound in preparing a product for preventing and / or treating gastric mucosal damage, and the application of the Chinese medicine compound in preparing a product for treating diseases by repairing gastric mucosal damage. The Chinese medicine compound includes the following components: cloves, turmeric, hericium erinaceus, monkey ring, sea cucumber sheath, mint and sodium bicarbonate. Experiments have shown that the Chinese medicine compound of the present invention can reduce the levels of inflammatory cytokines such as CRP, IL-6, PGE2 and TNF-α in rat serum, and at the same time, increase the level of SOD content in serum and reduce the level of MDA content, and has a good protective effect on gastric mucosal damage.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine compound and application thereof in preparing a product for preventing and treating gastric mucosal damage. Background Art

[0002] The stomach is an important organ of the digestive system. Its main function is to digest food. It is part of the digestive tract, connected to the esophagus above and the duodenum below. It is flat from front to back when empty and slightly thicker than the large intestine. In recent years, with economic growth, people are drinking more and more frequently, and the gastric mucosa is very susceptible to damage from alcohol, resulting in varying degrees of damage to the gastric mucosa, which in turn causes acute gastric injury, acute gastritis, etc., or causes irreversible effects on gastric function. Acute gastric injury can affect the body's normal digestive function. When the injury is severe, it can cause irreversible damage to the gastric mucosa or gastric tissue, and sometimes lead to gastric ulcers, acute and chronic gastritis or gastric bleeding, and even increase the risk of gastric cancer. At present, preventing acute gastric injury through drugs, health products, etc. is one of the effective clinical strategies.

[0003] Fuweisan capsule is a Chinese patent medicine currently on the market. It is mainly composed of Bletilla striata, Corydalis yanhusuo, Licorice, Astragalus, Angelica dahurica, White Peony Root and Cuttlebone. It has the effects of replenishing Qi and strengthening the spleen, reducing acid and relieving pain, stopping bleeding and promoting tissue regeneration. It is used for symptoms such as excessive gastric acid, vomiting blood and bloody stools, loss of appetite and thin body, gastric and duodenal ulcers, etc. Weisan is also a Chinese patent medicine currently on the market. The main ingredients are sodium bicarbonate, magnesium carbonate, costus root, Amomum villosum, cardamom, menthol, cinnamon, fennel, licorice, etc. It can be used for stomach pain caused by excessive gastric acid and indigestion caused by qi stagnation syndrome. It has a relieving effect on symptoms such as abdominal distension, abdominal pain, warm gas, loss of appetite, nausea and vomiting. At present, reports on the prevention and treatment of gastric mucosal damage in Chinese herbal compound are relatively rare. Summary of the invention

[0004] In view of the above technical problems, the present invention provides a Chinese medicine compound and its application in preparing a product for preventing and treating gastric mucosal damage.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0006] In a first aspect, the present invention provides a traditional Chinese medicine compound, comprising the following components: cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, mint and sodium bicarbonate.

[0007] In some embodiments, the Chinese medicine compound comprises the following components by weight: 1-20 parts of cloves, 1-10 parts of turmeric, 0.1-50 parts of Hericium erinaceus, 1-20 parts of monkey rings, 1-20 parts of sea cucumber sheaths, 0.1-10 parts of mint, and 0.05-1 parts of sodium bicarbonate;

[0008] Further, 3-15 parts of cloves, 2-7 parts of turmeric, 0.1-10 parts of Hericium erinaceus, 1-10 parts of monkey rings, 1-10 parts of sea cucumber sheaths, 0.1-6 parts of mint and 0.05-0.8 parts of sodium bicarbonate;

[0009] Further, 6-10 parts of cloves, 3-6 parts of turmeric, 1-5 parts of Hericium erinaceus, 1-5 parts of Hericium erinaceus, 1-8 parts of Cuttlefish sheath, 0.5-4 parts of mint and 0.1-0.5 parts of sodium bicarbonate;

[0010] Further, 8 parts of cloves, 4-6 parts of turmeric, 1-2 parts of Hericium erinaceus, 3 parts of monkey rings, 3-6 parts of sea cucumber sheaths, 1-2 parts of mint and 0.2 parts of sodium bicarbonate.

[0011] In a specific embodiment, the Chinese medicine compound is composed of the following components in parts by weight: 8 parts of cloves, 4-6 parts of turmeric, 1-2 parts of Hericium erinaceus, 3 parts of Hericium erinaceus, 3-6 parts of Cuttlefish sheath, 1-2 parts of mint and 0.2 parts of sodium bicarbonate.

[0012] In a second aspect, the present invention provides the use of the above-mentioned Chinese medicine compound in the preparation of a product for treating diseases by regulating inflammatory cytokines.

[0013] In some embodiments, the inflammatory cytokines include at least one of CRP, IL-6, PGE2, and TNF-α.

[0014] In some embodiments, the Chinese herbal compound can assist in the reduction of inflammatory cytokines and treat diseases by regulating the levels of MDA and SOD.

[0015] In some embodiments, the disease comprises at least one of gastric mucosal injury, gastric ulcer, acute gastritis, chronic gastritis and gastric cancer.

[0016] In a third aspect, the present invention provides use of the above-mentioned Chinese medicine compound in the preparation of a product for preventing and / or treating gastric mucosal damage.

[0017] In some embodiments, the gastric mucosal injury includes acute gastric mucosal injury and chronic gastric mucosal injury.

[0018] In some embodiments, the gastric mucosal damage is caused by alcohol damage and / or drug damage.

[0019] In a fourth aspect, the present invention provides the use of the aforementioned Chinese medicine compound in the preparation of a product for treating diseases by repairing gastric mucosal damage.

[0020] In some embodiments, the disease comprises gastric ulcer, gastritis, or gastric cancer.

[0021] The gastritis described in the present invention includes acute gastritis and chronic gastritis.

[0022] In a fifth aspect, the present invention provides a method for preparing the aforementioned Chinese medicine compound, comprising the following steps: grinding a formula amount of cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, and mint into dry powder, and mixing with sodium bicarbonate; or

[0023] The formula amounts of cloves, turmeric, hericium erinaceus, monkey ring, sea cucumber sheath and mint are extracted and purified to prepare extract dry powder, which is mixed with sodium bicarbonate.

[0024] In some embodiments, the extraction is water extraction and / or alcohol extraction.

[0025] In some embodiments, the preparation method is:

[0026] (1) extracting cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, and menthol with alcohol to obtain an alcohol extract;

[0027] (2) concentrating the alcohol extract and drying it to obtain extract powder;

[0028] (3) The extract powder and sodium bicarbonate are prepared into the Chinese medicine compound.

[0029] Preferably, the alcohol extraction in step (1) is performed by heating extraction using a lower alcohol as a solvent, preferably by reflux extraction; the lower alcohol is at least one of ethanol, propanol, butanol and pentanol.

[0030] The volume fraction of the lower alcohol is 10% or more, preferably 30% or more, more preferably 70-95%, more preferably 80-90% ethanol.

[0031] The amount of the lower alcohol used is 5-20 times, preferably 8-12 times, and more preferably 10-11 times the total amount of the extracted raw materials.

[0032] The alcohol extraction is performed at least once, preferably 1-3 times, and more preferably 2-3 times; the time for each extraction is 0.5-3 hours, preferably 1-2.5 hours, and more preferably 1-2 hours.

[0033] Preferably, the concentration in step (2) is concentration under reduced pressure at a temperature of 50-100°C, preferably 50-70°C.

[0034] In a sixth aspect, the present invention provides a pharmaceutical composition comprising the aforementioned Chinese medicine compound and pharmaceutically acceptable excipients.

[0035] In some embodiments, the pharmaceutical composition is in the form of tablets, pills, pellets, capsules, granules, powders, suppositories, powders, ointments, patches, injections, solutions, suspensions, sprays, lotions, drops, liniments or emulsions.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] The experimental results show that after intervention with the Chinese medicine compound, the degree of gastric mucosal injury in rats with acute gastric mucosal injury induced by anhydrous ethanol was significantly reduced, the SOD content level in the rat serum increased, the MDA content level decreased, and the levels of inflammatory cytokines such as CRP, IL-6, PGE2 and TNF-α decreased. This shows that the Chinese medicine compound provided by the present invention has a protective effect on acute gastric mucosal injury in rats induced by anhydrous ethanol, and the possible mechanism is to reduce the expression of inflammatory factors and the level of free radicals. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The results of microscopic observation of gastric tissue morphology of rats in each group (x10), where A is CON, B is MOD, C is ZFD, D is ZF1, E is ZF2, F is ZF3, and G is SJ.

[0039] Figure 2 These are the results of stereomicroscope observation of the stomach morphology of rats in each group, where A is CON, B is MOD, C is ZFD, D is ZF1, E is ZF2, F is ZF3, and G is SJ. DETAILED DESCRIPTION

[0040] The present invention is described below through specific embodiments to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto, and the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments.

[0041] The endpoints and any value of the scope disclosed in this article are not limited to the accurate scope or value, and these scopes or values ​​should be understood to include values ​​close to these scopes or values. For numerical ranges, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between separate point values, one or more new numerical ranges can be combined with each other, and these numerical ranges should be considered as specifically disclosed in this article. Unless the context clearly indicates otherwise, the singular form "one", "a kind of" and "described" as used herein include singular and plural indicators. The numerical range described by the endpoint is included in all numerical values ​​and fractions within the corresponding range, as well as the described endpoint.

[0042] the term

[0043] CRP is C-reactive protein, IL-6 is interleukin 6, PGE2 is prostaglandin E2, and TNF-α is tumor necrosis factor.

[0044] The "product" described in the present invention comprises the aforementioned Chinese herbal compound or pharmaceutical composition and acceptable excipients. In a specific embodiment, the Chinese herbal compound or pharmaceutical composition described in the present invention is provided in a drug in an effective amount (e.g., a therapeutically effective amount).

[0045] The "pharmaceutically acceptable excipients" described in the present invention include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients (such as cocoa butter and suppository wax), colorants, coating agents, sweeteners, flavoring agents and aromatics may also be present in the pharmaceutical composition.

[0046] The "drug" described in the present invention can be prepared by any method known in pharmacy. Generally speaking, these preparation methods include associating the aforementioned Chinese medicine compound (i.e., the first active ingredient) with a carrier or excipient and / or one or more other auxiliary ingredients, and then if necessary and / or desired, molding and / or packaging the product into a desired single dose or multiple dose unit.

[0047] The "drugs" of the present invention can be prepared according to known methods, such as the methods described in the general rules for preparation of the Chinese Pharmacopoeia (2020 edition), the Japanese Pharmacopoeia 16th edition, the United States Pharmacopoeia and the European Pharmacopoeia 9th edition. It depends on the dosage form.

[0048] The first active ingredient and pharmaceutically acceptable excipients in the "medicament" of the present invention will vary according to the attributes, body shape and / or condition of the subject to be treated and further according to the administration route of the composition. The medicament may contain between 0.1% and 100% (w / w) of the first active ingredient.

[0049] "Treatment" as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder or one or more symptoms of such condition or disorder to which the term applies, unless otherwise indicated. The term "treat" as used herein refers to the act of treating, as "treat" is defined immediately above.

[0050] The "effective amount" described in the present invention refers to an amount sufficient to induce a desired biological response. The effective amount of the active ingredients of the present invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. The effective amount is the amount of the first active ingredient described in the present invention in a single dose. In certain embodiments, the effective amount is the combined amount of the active ingredients described in the present invention in multiple doses.

[0051] The "therapeutically effective amount" described in the present invention is an amount sufficient to provide a therapeutic benefit in the treatment of a disease or sufficient to delay or minimize one or more symptoms associated with the disease. The therapeutically effective amount of a Chinese medicine composition or Chinese medicine extract means the amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease alone or in combination with other therapies. The term "therapeutically effective amount" may encompass an amount that improves overall therapy, reduces or avoids symptoms, signs or causes of a disease and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient to treat any disease or disease described.

[0052] The terms "subject" or "patient" as used in the present invention are well known in the art and are used interchangeably herein to refer to mammals, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. The term does not represent a particular age or sex. Thus, adult and newborn subjects, whether male or female, are encompassed.

[0053] The Chinese medicinal compound or pharmaceutical composition described in the present invention can also be used as one of the raw materials contained in medicines, functional foods or health products.

[0054] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention. The experimental methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0055] Example 1 Preparation of Chinese medicinal compound

[0056] The Chinese medicine compound is composed of the following components in parts by weight: 10 parts of cloves, 6 parts of turmeric, 5 parts of Hericium erinaceus, 5 parts of Hericium erinaceus, 8 parts of Cuttlefish sheath, 4 parts of mint and 0.5 parts of sodium bicarbonate.

[0057] ① Take the formulated amount of cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, and mint, mix them, add 10 times the amount of 85v / v% ethanol, reflux extraction 3 times, each time for 1.5h, combine the ethanol extracts, filter, recover ethanol, concentrate to a thick paste with a relative density of 1.10-1.12 (50°C), spray dry, and obtain extract powder.

[0058] ②Mix the extract powder with the formulated amount of sodium bicarbonate.

[0059] Example 2 Preparation of Chinese medicinal compound

[0060] The Chinese medicine compound is composed of the following components in parts by weight: 6 parts of cloves, 3 parts of turmeric, 1 part of Hericium erinaceus, 1 part of Hericium erinaceus, 1 part of Hericium erinaceus, 1 part of Cuttlefish sheath, 0.5 parts of mint and 0.1 parts of sodium bicarbonate.

[0061] ① Take the formulated amount of cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, and mint, mix them, add 10 times the amount of 85v / v% ethanol, reflux extraction 3 times, each time for 1.5h, combine the ethanol extracts, filter, recover ethanol, concentrate to a thick paste with a relative density of 1.10-1.12 (50°C), spray dry, and obtain extract powder.

[0062] ②Mix the extract powder with the formulated amount of sodium bicarbonate.

[0063] Example 3 Preparation of Chinese medicinal compound

[0064] The Chinese medicine compound is composed of the following components in parts by weight: 8 parts of cloves, 4.8 parts of turmeric, 1 part of Hericium erinaceus, 3 parts of Hericium erinaceus, 3.2 parts of Cuttlefish sheath, 1.2 parts of mint and 0.2 parts of sodium bicarbonate.

[0065] ① Take the formulated amount of cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath, and mint, mix them, add 10 times the amount of 85v / v% ethanol, reflux extraction 3 times, each time for 1.5h, combine the ethanol extracts, filter, recover ethanol, concentrate to a thick paste with a relative density of 1.10-1.12 (50°C), spray dry, and obtain extract powder.

[0066] ②Mix the extract powder with the formulated amount of sodium bicarbonate.

[0067] Comparative Example 1 Preparation of Chinese Medicine Compound

[0068] The Chinese medicinal compound is composed of the following components in parts by weight: 8 parts of cinnamon, 4.8 parts of turmeric, 1 part of Hericium erinaceus, 3 parts of Hericium erinaceus, 3.2 parts of Cuttlefish sheath, 1.2 parts of Licorice root and 0.2 parts of sodium bicarbonate.

[0069] ① Mix the formulated amount of cinnamon, turmeric, hericium erinaceus, monkey ring, sea cucumber sheath and licorice, add 10 times the amount of 85v / v% ethanol, reflux extraction 3 times, each time for 1.5h, combine the ethanol extracts, filter, recover ethanol, concentrate to a thick paste with a relative density of 1.10-1.12 (50°C), spray dry, and obtain extract powder.

[0070] ②Mix the extract powder with the formulated amount of sodium bicarbonate.

[0071] Example 4 Effect of Chinese herbal compound on gastric mucosal injury

[0072] SD rats were used as experimental subjects, and the efficacy of the drug-treated group was determined by observing the pathological sections of the gastric tissues of the rats treated with the Chinese herbal compound.

[0073] 1. Experimental Materials

[0074] 1.1 Experimental animals

[0075] 70 healthy SPF grade SD rats (130g-150g), male, were purchased from Guangdong Medical Experimental Animal Center. The animal breeding environment was 18-23℃, relative humidity 45%-55%, free access to food and water, and adaptive breeding for three days. All animal experiments were carried out in accordance with the guidelines of the Experimental Animal Center and approved by the Animal Ethics Committee.

[0076] 1.2 Reagents and Materials

[0077] Isoflurane (batch number: 2023071501, Shenzhen Ruiwode Life Science Technology Co., Ltd.); anhydrous ethanol (AR, Tianjin Zhiyuan Chemical Reagent Co., Ltd.); Sanjiu Weitai Granules (batch number: 2023121101, China Resources Sanjiu Pharmaceutical Co., Ltd.); double distilled water (prepared in the laboratory).

[0078] 1.3 Experimental instruments

[0079] Multifunctional microplate reader (model: SpectraMax i3X, Meigu Molecular Instruments (Shanghai) Co., Ltd.).

[0080] 2. Experimental methods

[0081] 2.1 Animal grouping and drug administration

[0082] 70 healthy SPF male SD rats, 6-7 weeks old (150±10g), were fed ad libitum and adaptively fed for one week. They were randomly divided into 7 groups according to body weight, including normal control group (CON), model group (MOD), positive drug Sanjiu Weitai (SJ) group, Chinese medicine compound comparison (ZFD) group, Chinese medicine compound 1 (ZF1) group, Chinese medicine compound 2 (ZF2) group and Chinese medicine compound 3 (ZF3) group, with 10 rats in each group. The normal group and the model group were given distilled water by gavage; the Sanjiu Weitai group was given 4.2g.kg Sanjiu Weitai liquid by gavage. -1 .d -1 The Chinese medicine compound group was gavaged with the corresponding Chinese medicine compound liquid 0.105g.kg -1 .d -1 .

[0083] Drugs were administered at a fixed time every day for 1 week. Rats were fasted but not allowed to drink water 24 hours before the last administration. 1.5 hours after the last administration, rats in all groups except the control group were given 1 ml of anhydrous ethanol, and rats in the normal group were gavaged with distilled water. SD rats were anesthetized by inhalation of isoflurane 1 hour later and samples were collected.

[0084] 2.2 Sample collection

[0085] After the last administration, 1 ml of anhydrous ethanol was gavaged, and 30 minutes later, all rats were anesthetized with isoflurane. Blood was collected from the abdominal aorta of the rats, and the blood in the procoagulant blood collection tube was centrifuged at 3500 rpm for 10 minutes at 4°C, and the upper serum was separated and stored in a -80°C refrigerator.

[0086] After blood collection, the stomach, liver, kidney, colon, and feces of the rats were collected by dissection, quenched with liquid nitrogen, and stored in a -80°C refrigerator. The removed stomach tissue was placed in a cryopreservation tube, and the rest was embedded and immersed in 4% tissue cell fixative. After the experimental rats were anesthetized by inhalation of isoflurane, the whole stomach was removed, the pylorus was ligated, and an appropriate amount of 10% paraformaldehyde solution was perfused. After fixation for 20 minutes, the stomach was cut open at the greater curvature and rinsed with saline.

[0087] 2.3 Serum biochemical test

[0088] Serum was collected to detect the activities of SOD, MDA, CRP, IL-6, PGE2, and TNF in rat serum. The specific operations for the determination of SOD and MDA content were carried out according to the instructions of the biochemical kit of Nanjing Jiancheng Biotechnology Co., Ltd. The determination of CRP, IL-6, PGE2, and TNF content was sent to Shanghai ELISA Biotechnology Co., Ltd.

[0089] 2.4 Gastric histopathological observation

[0090] The most severely damaged part of the gastric mucosa of each animal was excised, fixed in 10% formaldehyde solution, and routinely prepared for sectioning, HE staining, and observation under a microscope.

[0091] 2.5 Statistical analysis

[0092] SPSS27.0 statistical software was used to analyze the data, and the results were expressed as mean ± standard deviation. GraphPadPrism9.0 was used for drawing, independent sample t test was used for comparison between groups, one-way analysis of variance was used for comparison of means among multiple groups, and LSD was used for pairwise comparison. P<0.05 was considered statistically significant, and P<0.01 was considered highly statistically significant.

[0093] 3. Experimental results

[0094] 3.1 Results of inflammatory factor-related indicators

[0095] The levels of CRP, IL-6, PGE2 and TNF in the serum of rats were detected. The results showed that compared with the normal control group, the levels of CRP, IL-6, PGE2 and TNF-α in the serum of rats in the model group were significantly increased (P<0.05). Compared with the model group, the levels of CRP, IL-6, PGE2 and TNF-α in the serum of rats in each drug administration group were significantly decreased (P<0.05). Compared with the Chinese medicine compound control group, the levels of CRP, IL-6, PGE2 and TNF-α in the serum of rats in Chinese medicine compound group 1, group 2, group 3 and Sanjiu Weitai group were significantly decreased (P<0.05). Compared with the Chinese medicine compound group 1, there was no significant difference in the serum CRP, IL-6, PGE2 and TNF-α levels of the rats in the Chinese medicine compound group 2 (P>0.05), and the serum CRP, IL-6, PGE2 and TNF-α levels of the rats in the Chinese medicine compound group 3 and Sanjiu Weitai group were significantly decreased (P<0.05), as shown in Table 1.

[0096] Table 1 CRP, IL-6, PGE2 and TNF-α levels in serum of rats in each group

[0097]

[0098]

[0099] Different letters among the groups represent significant differences (P<0.05).

[0100] The present invention evaluates the degree of gastric damage by anhydrous ethanol and the intervention effect of the drug by detecting the levels of CRP, IL-6, PGE2 and TNF-α in the serum of each group of rats. Among them, CRP is one of the acute proteins, which is released by the inflammatory factor IL-6. Both IL-6 and TNF-α belong to the gold index for detecting inflammatory diseases. PED2, as a post-inflammatory factor, can participate in some inflammatory reactions. Therefore, the changes in the levels of CRP, IL-6, PGE2 and TNF-α reflect the degree of inflammatory reaction in rats after the Chinese medicine compound is given. The experimental results show that the Chinese medicine compound provided by the present invention can reduce the inflammatory reaction by regulating the expression levels of inflammatory cytokines such as CRP, IL-6, PGE2 and TNF-α, thereby protecting the gastric mucosa. Among them, the effect of the Chinese medicine compound prepared by Examples 1-3 is significantly better than that of the Chinese medicine compound prepared by Comparative Example 1; and the effect of the Chinese medicine compound prepared by Example 3 of the present invention is the best, which is basically the same as Sanjiu Weitai.

[0101] 3.2 Results of oxidative stress-related indicators

[0102] The contents of SOD and MDA in rat serum were detected. The results showed that compared with the blank control group, the MDA level in the serum of rats in the model group was significantly increased, and the SOD level was significantly decreased (P<0.05). Compared with the model group, the MDA level in the serum of rats in each drug administration group was significantly decreased (P<0.05), and the SOD level in the serum of rats in the Chinese medicine compound 1-3 group and Sanjiu Weitai group was significantly increased (P<0.05). The results are shown in Table 2.

[0103] Table 2 MDA and SOD levels in serum of rats in each group

[0104]

[0105] Different letters among the groups represent significant differences (P<0.05).

[0106] The present invention evaluates the degree of acute gastric injury and the intervention effect of drugs by detecting the SOD and MDA activity levels in the serum of each group of rats, wherein SOD and MDA are both gold indicators reflecting oxidative stress reactions. Studies have shown that after being treated with anhydrous ethanol, the MDA level in rat serum is significantly increased, and the SOD level is significantly reduced (P<0.05). The SOD and MDA levels in the rat serum of the Chinese medicine compound 1-3 group provided by the present invention are significantly adjusted (P<0.05). It is explained that the Chinese medicine compound prepared by Examples 1-3 of the present invention can protect the gastric mucosa by regulating the expression of SOD and MDA. At the same time, the effect of the Chinese medicine compound prepared by Example 3 is the best, exceeding the effect of Sanjiu Weitai. The Chinese medicine compound prepared by Comparative Example 1 cannot regulate the expression of MDA, and the effect of protecting the gastric mucosa is poor.

[0107] 3.3 Gastric histopathological observation results

[0108] The results showed that the gastric mucosa of the rats in the blank control group was almost free of damage and breakage, and the glands were neatly arranged. The epithelial cells of the rats in the model group were necrotic, the gastric mucosa was broken and shed, the glands were disordered, and a large number of glands in the lamina propria were dissolved. Compared with the model group, the degree of gastric mucosal damage in each drug-treated group was reduced, the gastric mucosa was flat, the surface was smooth, and the boundaries of the various layers of gastric tissue were clear, indicating that the Chinese herbal compound provided in Examples 1-3 of the present invention has a good protective effect on acute gastric mucosal damage caused by anhydrous ethanol, such as Figure 1 shown.

[0109] Example 5 Effect of Chinese herbal compound on gastric injury

[0110] Healthy SPF male SD rats were randomly divided into normal control group (CON), model group (MOD), Sanjiu Weitai group (SJ), Chinese medicine compound comparison 1 (ZFD) group, Chinese medicine compound 1 (ZF1) group, Chinese medicine compound 2 (ZF2) group, and Chinese medicine compound 3 (ZF3) group according to body weight. The normal group and model group were given distilled water by gavage; Sanjiu Weitai group was given 4.2 g.kg Sanjiu Weitai liquid by gavage. - 1 .d -1 The Chinese medicine compound group was gavaged with the corresponding Chinese medicine compound liquid 0.105g.kg -1 .d -1 .

[0111] The drugs were administered at a fixed time every day for 1 week in a row. The rats were fasted but not allowed to drink water for 24 hours after the last administration. 1.5 hours after the last administration, all the animals in the experimental groups except the blank control were given 1.0 mL of anhydrous ethanol each. The animals were killed 1 hour later, the whole stomach was exposed, the pylorus was ligated, and an appropriate amount of 10% formalin solution was perfused. The stomach was fixed for 20 minutes, then cut open along the greater curvature of the stomach, the stomach contents were washed, the gastric mucosa was unfolded, and the length and width of the bleeding point or bleeding band were measured with a vernier caliper under a stereoscopic dissecting microscope or with the naked eye.

[0112] [Gastric Damage Evaluation]

[0113] Evaluate the gastric mucosal surface damage by referring to the auxiliary gastric mucosal damage protection function evaluation method to more objectively display the gastric mucosal damage situation.

[0114] Table 3. Gross observation scoring criteria for acute anhydrous ethanol injury

[0115]

[0116] Total score = bleeding point score + length score + (width score × 2)

[0117] Observation indicators: The degree of gastric mucosal injury in each experimental group was expressed by injury incidence (%), injury integral index and injury inhibition rate (%).

[0118] Injury incidence (%) = number of rats with bleeding or ulcers in a group / number of rats in the group × 100%;

[0119] Injury score index = total injury score of each group / number of animals in each group;

[0120] Damage inhibition rate (%) = (AB) / A×100%, where A and B are the damage scores of the model group and the test group, respectively.

[0121] The results are shown in Table 4.

[0122] Table 4 Gastric injury scores of each group

[0123]

[0124] Note: Compared with the model group, *P<0.05

[0125] The results showed that the injury incidence of the model was 100% after modeling with anhydrous ethanol, indicating that the modeling was successful. Compared with the model group, the injury scores of the Sanjiu Weitai group and the Chinese medicine compound 1-3 groups were significantly reduced (P<0.05), and there was no difference in the Chinese medicine compound control group (P>0.05). From the perspective of injury inhibition rate, the inhibition effect of the Chinese medicine compound 3 group was the most obvious, reaching 67%. The results showed that Sanjiu Weitai and the Chinese medicine compound prepared by Examples 1-3 of the present invention have a good effect on improving gastric mucosal injury caused by anhydrous ethanol, among which the Chinese medicine compound prepared by Example 3 has the best effect.

[0126] [Stereoscopic observation]

[0127] The results showed that the gastric mucosa of the control rats in the blank group was smooth, without congestion, edema, or bleeding; the gastric mucosa of the rats in the model group showed flake and strip bleeding, most of which showed diffuse inflammation and large-area erosion. Compared with the model group, bleeding and inflammation were observed in the Sanjiu Weitai group, and the three Chinese medicine compound groups showed significant improvement, with only tiny bleeding spots. The Chinese medicine compound control group showed no significant improvement, such as Figure 2 shown.

[0128] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. Use of a Chinese medicine compound in the preparation of a health product with an auxiliary protective function for gastric mucosal damage, the Chinese medicine compound being prepared from the following components by weight: 1-20 parts of cloves, 1-10 parts of turmeric, 0.1-50 parts of hericium erinaceus, 1-20 parts of monkey earrings, 1-20 parts of sea cucumber sheaths, 0.1-10 parts of mint and 0.05-1 part of sodium bicarbonate.

2. Use of a Chinese herbal compound in the preparation of a medicine for preventing and treating gastric mucosal damage, the Chinese herbal compound being made of the following components by weight: 1-20 parts of cloves, 1-10 parts of turmeric, 0.1-50 parts of Hericium erinaceus, 1-20 parts of monkey earrings, 1-20 parts of sea cucumber sheaths, 0.1-10 parts of mint and 0.05-1 part of sodium bicarbonate.

3. Use of a Chinese medicine compound in the preparation of a medicine for treating diseases by repairing gastric mucosal damage, the Chinese medicine compound being prepared from the following components by weight: 1-20 parts of cloves, 1-10 parts of turmeric, 0.1-50 parts of Hericium erinaceus, 1-20 parts of monkey earrings, 1-20 parts of sea cucumber sheaths, 0.1-10 parts of mint and 0.05-1 parts of sodium bicarbonate; The disease is gastric ulcer or acute gastritis.

4. A Chinese medicinal compound for preventing and treating gastric mucosal damage, characterized in that: The invention is prepared from the following components by weight: 1-20 parts of cloves, 1-10 parts of turmeric, 0.1-50 parts of hericium erinaceus, 1-20 parts of monkey earrings, 1-20 parts of sea cucumber sheaths, 0.1-10 parts of mint and 0.05-1 parts of sodium bicarbonate.

5. A method for preparing the Chinese medicinal compound according to claim 4, characterized in that: Grind the formulated amount of cloves, turmeric, Hericium erinaceus, Hericium erinaceus, Cuttlefish sheath and mint into dry powder and mix with sodium bicarbonate; or The formula amounts of cloves, turmeric, hericium erinaceus, monkey earrings, sea cucumber sheaths and mint are extracted and purified to prepare extract dry powder, which is mixed with sodium bicarbonate.

6. A pharmaceutical composition for preventing and treating gastric mucosal damage, characterized in that: The invention comprises the Chinese medicinal compound according to claim 4 and pharmaceutically acceptable excipients.

Images